Atezolizumab: A PD-L1-Blocking Antibody For Bladder Cancer
FDA Approves Atezolizumab for Bladder Cancer
FDA Approves New, Targeted Treatment For Bladder Cancer …
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer
FDA Approval Summary: Atezolizumab For The Treatment …
FDA approves atezolizumab for first-line treatment of
FDA Approves Atezolizumab In Bladder Cancer
Tecentriq (atezolizumab) FDA Approval History - Drugs.com
Atezolizumab: A PD-L1-Blocking Antibody For Bladder …
May 18, 2016. The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product...
FDA Approves Atezolizumab In Bladder Cancer
19/04/2017 · FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum‐Containing Chemotherapy Yang‐Min Ning , * a Daniel Suzman , a V. Ellen Maher , a Lijun Zhang , a Shenghui Tang , a Tiffany Ricks , a Todd Palmby , a Wentao Fu , a Qi Liu , a Kirsten B. Goldberg , a Geoffrey Kim , a and …
FDA Approves Atezolizumab For First-line Treatment Of …
18/05/2016 · Atezolizumab previously received a breakthrough therapy designation from the FDA for the treatment of patients with PD-L1—positive metastatic bladder cancer. The accelerated approval is ...
Atezolizumab FDA Indication For Pretreated Bladder …
Atezolizumab has been FDA approved as second-line therapy for advanced bladder cancer. This accelerated approval was based on phase II trial data in patients with metastatic bladder cancer that showed unexpected and durable tumor responses.
FDA Approves Atezolizumab For Bladder Cancer - Medscape
19/05/2016 · Atezolizumab previously received a breakthrough therapy designation from the FDA for the treatment of patients with PD-L1—positive metastatic bladder cancer. The accelerated approval is contingent on results from an ongoing confirmatory phase III study, IMvigor 211 (NCT02302807), which is comparing atezolizumab with chemotherapy in patients with locally …